SCHEMBL3671049

SCHEMBL3671049

CCn1c(=O)c(-c2cc(C(=O)NC3CC3)cc(F)c2C)cc2cnn(-c3ccccc3F)c21

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 20/20 0.69
CYP3A4 P08684 3/20 0.69
LCK P06239 2/20 0.66
KIT P10721 2/20 0.66
KDR P35968 2/20 0.66
MAPKAPK2 P49137 4/20 0.54
MAPK11 Q15759 2/20 0.54
MAPK13 O15264 1/20 0.54
RAF1 P04049 1/20 0.54
PDGFRA P16234 1/20 0.54
MAPK12 P53778 1/20 0.54
KCNH2 Q12809 1/20 0.54
BUB1 O43683 1/20 0.44
CYP2C9 P11712 1/20 0.44
PRKACG P22612 1/20 0.44
ACSL5 Q9ULC5 1/20 0.44
STK24 Q9Y6E0 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3643649 0.89 MAPK14 (0.83) MAPK14CYP3A4LCKKITKDR
SCHEMBL3637700 0.84 MAPK14 (0.79) MAPK14CYP3A4LCKKITKDR
SCHEMBL3674202 0.82 MAPK14 (0.78) MAPK14CYP3A4LCKKITKDR
SCHEMBL3632611 0.82 MAPK14 (1.00) MAPK14CYP3A4LCKKITKDR
SCHEMBL3636266 0.80 MAPK14 (0.82) MAPK14CYP3A4LCKKITKDR
SCHEMBL3640835 0.80 MAPK14 (0.82) MAPK14CYP3A4LCKKITKDR
SCHEMBL3668926 0.80 MAPK14 (1.00) MAPK14CYP3A4LCKKITKDR
SCHEMBL1883542 0.79 MAPK14 (0.66) MAPK14CYP3A4LCKKITKDR
SCHEMBL1886774 0.78 MAPK14 (0.66) MAPK14CYP3A4LCKKITKDR
SCHEMBL3634287 0.74 MAPK14 (0.71) MAPK14CYP3A4LCKKITKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7846944-B2 Pyrazolo-pyridinone compounds and methods of use thereof AMGEN INC. (US) 2010-12-07 US claimed
US-20090012299-A1 Pyrazolo-pyridinone compounds and methods of use thereof AMGEN INC. (US) 2009-01-08 US claimed
US-7846944-B2 Pyrazolo-pyridinone compounds and methods of use thereof AMGEN INC. (US) 2010-12-07 US disclosed
EP-2152704-A1 PYRAZOLO-PYRIDINONE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE Amgen, Inc (US) 2010-02-17 EP disclosed
US-20090012299-A1 Pyrazolo-pyridinone compounds and methods of use thereof AMGEN INC. (US) 2009-01-08 US disclosed
WO-2008137176-A1 PYRAZOLO-PYRIDINONE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE AMGEN INC. (US) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012299-A1 Pyrazolo-pyridinone compounds and methods of use thereof MAPK1, MAP3K1, MAP4K2 MAPK14 41/4885CYP3A4 964/4885LCK 527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.